School of Medicine


Showing 1-10 of 25 Results

  • Laura K. Bachrach

    Laura K. Bachrach

    Professor of Pediatrics (Endocrinology) at the Lucile Salter Packard Children's Hospital

    Current Research and Scholarly Interests Prevention of osteoporosis begins in childhood and adolescence by measures that maximize acquistion of bone mineral during the critical adolescent years. Body mass, calcium nutriture, physical activity, growth and sex steroid hormones, and genetic factors are all thought to be important determinants of bone mass although the relative contribution of each remains controversial.

  • Bruce Buckingham

    Bruce Buckingham

    Professor of Pediatrics (Endocrinology) at the Lucile Salter Packard Children's Hospital, Emeritus

    Current Research and Scholarly Interests My major interest is in type 1 diabetes mellitus, continuous glucose sensor, and the development of an artificial pancreas. Other research interests include using continuous glucose monitoring and algorithms to control blood glucose levels in intensive care units.

  • Nicolas Cuttriss

    Nicolas Cuttriss

    Clinical Assistant Professor, Pediatrics - Endocrinology and Diabetes

    Bio Dr. Cuttriss serves as Director of Project ECHO Diabetes at Stanford University. Prior to joining Stanford, Dr. Cuttriss served as the first pediatric endocrinologist for the University of New Mexico Project ECHO Institute ENDO teleECHO (www.echo.unm.edu) to democratize specialty knowledge and expand patients’ access to critical care and services in rural and underserved communities. Dr. Cuttriss co-founded and serves of chairman of the Board of AYUDA (www.ayudavolunteer.org), a global health volunteer organization that empowers youth to serve as agents of change for youth with diabetes. Dr. Cuttriss has supported diabetes outreach initiatives in over 10 countries, trained and placed over 700 students abroad. Dr. Cuttriss has special interest in telehealth, diabetes, and supporting vulnerable and underserved diabetes communities in the United States and globally.

  • Anna L Gloyn

    Anna L Gloyn

    Professor of Pediatrics (Endocrinology) and, by courtesy, of Genetics

    Bio Dr Anna Gloyn has recently relocated to Stanford University from the University of Oxford, UK where she was based for fifteen years at the Oxford Centre for Diabetes Endocrinology and Metabolism and the Wellcome Centre for Human Genetics.

    Anna completed her DPhil at the University of Oxford under the supervision of the late Professor Robert Turner. Her post-doctoral training was carried out at the University of Exeter under the mentorship of Professors Andrew Hattersley & Sian Ellard and at the University of Pennsylvania in Philadelphia under the mentorship of Professor Franz Matschinsky. In 2004 she returned to Oxford with a Diabetes UK RD Lawrence Career Development Fellowship and established her own research group focused on understanding beta-cell function through the investigation of genetic variants causally implicated in monogenic diabetes. Since her return to Oxford Dr Gloyn received continuous personal funding from Diabetes UK, the Medical Research Council and the Wellcome Trust. In 2011 she was awarded a prestigious Wellcome Senior Fellowship in Basic Biomedical Science which she successfully renewed in 2016.

    The consistent focus of Anna’s research has been using naturally occurring mutations in humans as tools to identity critical regulatory pathways and insights into normal physiology. Her early post-doctoral research led to the identification a new genetic aetiology for permanent and transient neonatal diabetes due to KCNJ11 mutations and resulted in one of the first examples of precision medicine, where the determination of the molecular genetic aetiology lead to improved treatment options for patients. Whilst in Oxford, Anna's team discovered a novel genetic cause of constitutive insulin sensitivity in humans due to mutations in the PTEN gene highlighting the complex interplay between pathways involved in cell-growth and metabolism.

    Anna's current research projects are focused on the translation of genetic association signals for type 2 diabetes and glycaemic traits into cellular and molecular mechanisms for beta-cell dysfunction and diabetes. Her group uses a variety of complementary approaches, including human genetics, functional genomics, physiology and islet-biology to dissect out the molecular mechanisms driving disease pathogenesis.

    Anna is an active member of multiple internal genetic discovery efforts including: NIH/Pharma funded Accelerated Medicines Partnership, DIAGRAM (Diabetes Genetics Replication and Meta-analysis), MAGIC (Meta-analysis of Glucose and Insulin traits Consortium), Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-Ethnic Samples (T2D-GENES) and the Genetics of Type 2 Diabetes (GoT2D). She was also involved in the IMI funded STEMBANCC project which focused on delivering human IPS cell derived beta-cell models for drug discovery efforts.

    Anna is also involved in several initiatives under the Human Islet Research Network (HIRN): the NIDDK funded Human Pancreas Atlas Programme (HPAP) for Type 2 Diabetes, and the Integrated Islet Phenotyping Programme (IIPP).

Latest information on COVID-19